Welcome to our dedicated page for Lakefront Biotherapeutics NV SEC filings (Ticker: LKFT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Lakefront Biotherapeutics NV's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Lakefront Biotherapeutics NV's regulatory disclosures and financial reporting.
Lakefront Biotherapeutics reported that Bank of America Corporation crossed a key ownership threshold under Belgian transparency rules. On May 13, 2026, Bank of America and its affiliates moved above 5% of Lakefront’s voting rights through a mix of shares and derivatives.
As of May 20, 2026, Bank of America held 623,434 direct voting rights and 5,502,802 equivalent financial instruments, together representing 9.30% of Lakefront’s currently outstanding 65,897,071 shares. The position is spread across several entities, including BofA Securities and Merrill Lynch International, via rights of use, recall, options, and swaps.